Between June 1989 and November 1996, a total of 22 High-dose busulfan (BU) is widely used in combined chemotherapy before allogeneic or autologous bone patients with various hematological malignancies or immunodeficiencies received allogeneic BMT (14 cases) or marrow transplantation. Convulsions are reported as a side-effect of high-dose BU. We recorded electroenceautologous peripheral blood stem cell transplants (eight cases) after preparation with high-dose BU (Table 1) . Thirphalograms (EEGs) before and on the third day of BU administration in 22 patients. Abnormal EEGs were teen patients had acute lymphoblastic leukemia (ALL): eight were in first complete remission (CR) and five were observed on the third day in 13 cases (59%). These patients were older (P Ͻ Ͻ Ͻ 0.05) and had had larger doses in second CR. Five patients had acute non-lymphoblastic leukemia (ANLL): three were in first CR and two were of BU (P Ͻ Ͻ Ͻ 0.025) than the nine patients with normal EEGs. Convulsions occurred in two of the 22 patients, in second CR. Five patients had other diseases: two nonHodgkin's lymphoma (NHL), one Wiskott Aldrich synone of whom was receiving prophylaxis with phenytoin.
Between June 1989 and November 1996, a total of 22 High-dose busulfan (BU) is widely used in combined chemotherapy before allogeneic or autologous bone patients with various hematological malignancies or immunodeficiencies received allogeneic BMT (14 cases) or marrow transplantation. Convulsions are reported as a side-effect of high-dose BU. We recorded electroenceautologous peripheral blood stem cell transplants (eight cases) after preparation with high-dose BU (Table 1) . Thirphalograms (EEGs) before and on the third day of BU administration in 22 patients. Abnormal EEGs were teen patients had acute lymphoblastic leukemia (ALL): eight were in first complete remission (CR) and five were observed on the third day in 13 cases (59%). These patients were older (P Ͻ Ͻ Ͻ 0.05) and had had larger doses in second CR. Five patients had acute non-lymphoblastic leukemia (ANLL): three were in first CR and two were of BU (P Ͻ Ͻ Ͻ 0.025) than the nine patients with normal EEGs. Convulsions occurred in two of the 22 patients, in second CR. Five patients had other diseases: two nonHodgkin's lymphoma (NHL), one Wiskott Aldrich synone of whom was receiving prophylaxis with phenytoin. Gamma aminobutyric acid (GABA), a natural mediator drome (WAS), and one chronic myelogenous leukemia (CML). of defense against epileptic activity, concentrations in cerebrospinal fluid measured before and after adminis-
The conditioning regimen used consisted of BU given orally over 4 consecutive days, followed by cyclophostration of BU showed no definite changes. Keywords: busulfan; convulsion; electroencephalogram; phamide (CY) and/or other drugs. The dose of BU was 16 mg/kg in older children and 500 mg/m 2 in younger chil-GABA dren. Every patient except when otherwise stated received anticonvulsant prophylaxis with phenytoin (4 mg/kg intravenously as a loading dose followed by 4 mg/kg/day High-dose busulfan (BU) is increasingly used in conditionorally). Phenytoin administration was begun 12 h before the ing regimens for bone marrow transplantation (BMT).
first dose of BU and continued until at least 24 h after the Liver dysfunction is reported as a side-effect of high-dose last dose. BU. Since the introduction of high-dose BU in conditioning EEGs were recorded before, and on the third day of BU regimens for bone marrow transplantation, several cases of administration and were evaluated by pediatric neurolconvulsions have been reported, especially in adults. [1] [2] [3] [4] [5] [6] In ogists. The administration of BU and phenytoin, and schedthe literature, convulsion occurs in adults after the second ule for EEG recording are illustrated in Figure 1 . GABA day of therapy, more frequently after the last dose of BU.
concentrations in cerebrospinal fluid samples were measPhenytoin is usually given to adult patients receiving highured in 12 of 22 patients, four with normal EEGs and eight dose BU, but convulsions still occur after prophylaxis. In with abnormal EEGs before and on the third day of BU children, the acute neurotoxicity of BU is reported to be administration using high performance liquid chromatogradose dependent. Vassal et al 4 reported a significant differphy (HPLC). ence between children receiving 16 mg/kg and those receiv-A t test or Wilcoxon test was used to compare age and ing 600 mg/m 2 in terms of probability of developing acute doses of BU. The paired t test was used to compare the neurotoxicity. However, several studies are available which concentration of GABA before and after administration examined the EEG as a possible index of neurotoxicity durof BU. ing BU administration. 7 We recorded electroencephalograms and measured gamma aminobutyric acid (GABA), a natural mediator of defense against epileptic activity, from Results cerebrospinal fluid samples taken before and on the third day of BU.
EEGs before administration of BU were normal in 20 of 22 patients. One of the two patients with an abnormal EEG before BU had leukoencephalopathy diagnosed by MRI, associated with cranial radiation and methotrexate. EEGs myelogenous leukemia in first complete remission who received BU while taking phenytoin. On the third day of BU administration his EEG revealed polyspikes without convulsions. Twenty hours after the last dose of BU, he suffered a generalized tonic-clonic seizure of 3 min duration with loss of consciousness, and received intravenous diazepam. He had no other complication, including liver dysfunction, and is alive and disease-free. Compared to patients with normal EEGs, patients with abnormal EEGs were older in age (P Ͻ 0.05) and received (Table 2) . Sex, disease and followed by 4 mg/kg/day oral administration, was begun 12 h before the past history of cranial irradiation were not associated with first dose of busulfan and continued until at latest 24 h after the last dose.
EEG abnormalities.
EEGs were recorded before and on the third day of busulfan.
GABA concentrations measured in cerebrospinal fluid decreased on the third day of BU administration in five of 12 patients tested including those with and without EEG diffuse polyspikes in one patient and diffuse spike-andabnormalities. In the remaining seven patients, GABA waves in 12 patients. An example is shown in Figure 2 .
increased, and thus, no definite tendency was observed in The EEGs of the two patients with abnormalities before the changes of GABA in CSF between patients with and BU worsened after administration of BU.
without EEG abnormalities (Figure 3 ). Convulsions occurred in two patients. One was a 15-year-old girl with acute lymphoblastic leukemia in second remission who received BU without administration of antiDiscussion convulsant prophylaxis. On the third day of BU administration (after the 8th dose), she suffered a generalized
The mechanism of neurotoxicity with BU is not clear. However, it is known that BU does not bind tightly to tonic-clonic convulsion of 2 min duration with loss of consciousness which resolved spontaneously. No abnormality plasma proteins and easily crosses the blood-brain barrier soon after oral administration, and that CSF concentration was noted on brain CT. Her EEG after the convulsion revealed spontaneous spike-and-wave complexes. She was is similar to, and sometimes significantly higher than that in plasma. Thus, convulsions occurring after the last dose given oral phenobarbital treatment thereafter but died with hepatic veno-occlusive disease (VOD) on day +56 postof BU could be considered to be due to prolonged brain exposure to BU and/or to its metabolites. BMT. The other case was a 16-year-old boy with acute 513.68 ± 8.60** 475.02 ± 14.87** *P Ͻ 0.05; **P Ͻ 0.025.
We noted two cases of BU-associated convulsions in 22 barbital, clonazepam and phenytoin are usually given to patients receiving high-dose BU. However, even with the BMT recipients conditioned with high-dose BU. The overall incidence of convulsions was 9.1%. However, in 13 out use of phenytoin, some patients are reported to suffer convulsions. It is known that serum concentrations of phenyof 22 cases (59%), abnormal EEGs were recorded after administration of BU. Since almost all patients received toin increase gradually with oral administration, and may sometimes not assume high enough levels to prevent prophylaxis with phenytoin, this prophylactic procedure may be effective in preventing convulsions due to BU. We convulsions due to BU. In this context, we recommend that the first dose of phenytoin should be administered compared factors between patients with and without abnormal EEGs. EEG abnormalities correlated with age, and intravenously. Gamma aminobutylic acid (GABA), a major neurodose of BU confirming an earlier report which showed that neurotoxicity with BU is dose-dependent in children. 4 transmitter in the brain, may be a natural mediator for defense against epileptic activity. It has been speculated Recently it was shown that 16 mg/kg of BU was insufficient for conditioning in younger children and larger doses that decreases in GABA are associated with convulsions due to penicillins, cephalosporins, and procaine. 8 Furtherof BU were recommended. However, as is shown in the present study, a high dose of BU promotes EEG abnormore, concentrations of GABA in cerebrospinal fluid have been reported to be low in patients suffering from conmality, a possible indicator of neurotoxicity. Thus, convulsion prophylaxis is important for these patients. Phenovulsions. 9 We measured GABA in cerebrospinal fluid sidered when administering larger doses of BU to children, especially older ones. Nevertheless, the possibility of neurotoxicity must be con-
